Pulmonx (LUNG) Q1 2026 earnings review
Top-Line Contraction Persists, But Cost Discipline Drives Margin Expansion
Pulmonx's Q1 2026 results reflect a company deep in transition. Total revenue fell 9% YoY to $20.6M, driven by dual headwinds: a prolonged US sales turnaround (-7% YoY) and a regulatory halt in China that dragged international sales down 12%. However, management's aggressive pivot toward profitability—a theme established in late 2025—is bearing fruit. Gross margin expanded sharply to 78% (up from 73% a year ago), and operating expenses dropped 6%. The reiteration of FY26 guidance ($90-$92M revenue) implies management expects a steep, back-half weighted recovery once the sales force matures and China resumes ordering.
🐂 Bull Case
Despite losing operating leverage on the top line, Pulmonx expanded gross margins to 78% and reduced Q1 OpEx by 6% to $29.0M, proving out their cost restructuring initiatives.
Excluding the bureaucratic delay in China, international revenue grew an impressive 22% YoY, showing that core OUS markets are fundamentally healthy.
🐻 Bear Case
US revenue contracted 7% YoY. While an improvement over Q4's 11% decline, it indicates the 'refreshed US commercial strategies' and newly hired sales force have yet to generate meaningful positive leverage.
Maintaining the $90-$92M FY26 revenue guide requires a dramatic acceleration in the second half of the year, leaving zero room for further delays in China or US sales force missteps.
⚖️ Verdict: ⚪
Neutral. The top-line deceleration is alarming, but the surgical execution on margins and expense control prevents a disaster. Pulmonx is successfully extending its cash runway while it attempts to fix its commercial engine.
Key Themes
China Regulatory Delay Crushes International Momentum
International revenue abruptly reversed, falling 12% YoY to $7.3M. Management explicitly blamed 'a lack of sales into China as we await the renewal of our registration certificate.' This single point of failure completely masked strong underlying demand, as international revenue excluding China actually accelerated, growing 22% YoY.
US Commercial Reboot Taking Time
US sales declined 7% YoY to $13.3M. Management cited 'early signs of progress' and noted the sales organization is now 'fully staffed.' However, the data contradicts the optimism in the short term: relying on a massive influx of new reps (who historically carry a 6-9 month productivity ramp) means the US turnaround will likely remain a drag through Q2.
Aggressive Cost Control and Gross Margin Expansion
Management's commitment to financial discipline is yielding undeniable results. Gross margin hit 78% in 26Q1 (up from 73% in 25Q1), and total operating expenses dropped 6% to $29.0M. This discipline allowed the company to slightly reduce its net loss (-$13.7M vs -$14.4M in 25Q1) despite an $1.9M drop in total revenue.
AeriSeal Clinical Program Advancing
CEO Glen French highlighted ongoing progress in advancing clinical programs. The flagship effort is the CONVERT II pivotal trial for AeriSeal, which seeks to treat patients with collateral ventilation. If successful, this technology is expected to expand the company's total addressable market globally by an estimated 20%.
Trade and FX Headwinds Persist
The macro environment continues to act as a friction point. Pulmonx reported a 12% total revenue decline on a constant currency basis vs a 9% reported drop, indicating FX fluctuations continue to distort the top line. Furthermore, past concerns regarding potential tariffs on international components continue to inform management's cautious full-year guidance.
Other KPIs
Stable. The loss came in essentially flat compared to -$8.5M in 25Q1. Given the top-line shock, stabilizing EBITDA points to the effectiveness of the >10% structural cost reductions implemented in late 2025.
Down sequentially from $69.8M at the end of 2025, representing an $8.2M burn in Q1. This remains aligned with management's FY26 goal of limiting annual cash burn to $23M. The recently refinanced 5-year interest-only credit facility (extending to 2031) solidifies the balance sheet.
Guidance
Accelerating dramatically in implied H2. Maintained guidance implies flat to 2% growth over FY25's $90.5M. With Q1 revenue down 9%, management is heavily dependent on a massive snap-back in the second half of 2026, driven by U.S. sales rep maturity and the return of Chinese ordering.
Stable. Maintained expectations, though Q1's actual result of 78% provides a comfortable buffer for the remainder of the year. Geographic mix shifts (e.g., lower-margin China distributor sales returning) will likely pull the average down slightly in H2.
Stable. Reaffirmed guidance, which includes ~$19M of non-cash stock-based compensation. Stripping out SBC, this implies cash OpEx of roughly $94-96M for the year, underscoring the shift away from growth-at-all-costs spending.
Key Questions
China Registration Timeline
With China registration renewal completely halting sales in the region, what is the exact timeline for approval, and does the FY26 guidance assume a full recapture of Q1's lost volume, or simply a resumption of normal run-rate ordering?
US Sales Force Productivity
You noted the US sales organization is now 'fully staffed.' What are the early leading indicators (like patient workups or StratX scans) showing regarding the productivity of these new hires compared to tenured reps?
Gross Margin Sustainability
Gross margin printed an impressive 78% this quarter. How much of this beat was due to the absence of lower-margin China distributor sales, and is the 75% full-year guidance intentionally conservative?